Biogen (BIIB) has reached a deal worth up to $850M with TJ Bio to acquire exclusive rights in Greater China for felzartamab, an antibody therapy designed to target various immune-mediated disorders, ...

Biogen Inc. (Nasdaq: BIIB) and TJ Biopharma (“TJ Bio”) today announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio’s exclusive rights to ...

The manufacturing of the drug will be retained by TJ Biopharma at its site in Hangzhou, which would make felzartamab China’s ...

April 20 (Reuters) - Biogen said on Monday it had agreed to pay up to $850 million to acquire exclusive rights in Greater ...

Biogen has entered into an agreement with TJ Biopharma (TJ Bio) to acquire exclusive rights to felzartamab in the Greater ...

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building on an existing partnership with local drugmaker TJ Biopharma. The ...

Biogen has agreed to pay up to $850 million to acquire TJ Bio's exclusive rights to felzartamab in the Greater China region, giving it worldwide rights to the investigational drug that is currently in ...

(RTTNews) - Eisai Co., Ltd. (EII.SG, ESALY.PK, 4523.T) and Biogen Inc. (BIIB) announced that the National Medical Products Administration (NMPA) of China has granted priority review for the Biologics ...

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner Advancing felzartamab – a CD38-directed ...

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner Advancing felzartamab – a CD38-directed ...